Investor Relations

About Natera

Natera™ is a global leader in cell-free DNA (cfDNA) testing with a focus on women’s health, oncology, and organ health.

 

Our cutting-edge cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and AI, allowing detection down to a single molecule in a tube of blood. We’ve leveraged this platform to develop the most accurate non-invasive prenatal test on the market (Panorama™), the first tumor-specific assay for truly individualized cancer care (Signatera™), and best-in-class rejection assessment for kidney transplantation (Prospera™), among other transformative cfDNA tests.

 

Natera has performed more than 3 million cfDNA tests in its laboratories, more than any other, studied over 1.3 million patients and has been published in over 50 peer reviewed publications.

 
 
natera

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News

May 16, 2022
Matthew Rabinowitz, Natera Co-Founder and Executive Chairman of the Board, Makes Additional Investment in Natera
AUSTIN, Texas , May 16, 2022 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a global leader in cell-free DNA testing, announced that Matthew Rabinowitz , co-founder and Executive Chairman of Natera, together with his family's trust, have recently acquired a total of 470,000 shares of Natera stock
May 5, 2022
Natera Reports First Quarter 2022 Financial Results
AUSTIN, Texas , May 5, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ:  NTRA), a global leader in cell-free DNA testing, today reported financial results for the first quarter ended March 31, 2022 and provided an update on recent business progress and financial outlook.
May 2, 2022
Natera Announces First Quarter 2022 Earnings Conference Call
AUSTIN, Texas , May 2, 2022 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its first quarter ended March 31, 2022 , after the market close on May 5, 2022. Natera will host a conference call and webcast at 1:30
April 26, 2022
Natera Announces Definitive Study to Evaluate the Clinical Utility of Renasight in the Diagnosis and Management of Chronic Kidney Disease (CKD)
RenaCARE study expected to be fully enrolled by end of Q2 of 2022 AUSTIN, Texas , April 26, 2022 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the RenaCARE (Renasight Clinical Application, Review and Evaluation) study - a real world,
April 19, 2022
Large Real-World Study with Renasight Genetic Test Highlights High Diagnostic Yield for Patients with Chronic Kidney Disease
AUSTIN, Texas , April 19, 2022  /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a global leader in cell-free DNA testing, announced the results of a large, real-world study 1 demonstrating a high yield rate for positive genetic findings with its Renasight™ test in patients with chronic kidney

Upcoming Events

More events are coming soon.

Past events